Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma

Veterinary and Comparative Oncology

Volumn 10, Issue 3, 2012, Pages 214-222

  Marley, K ^a   Maier, C S ^a   Helfand, S C ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Cell signalling; Metastasis; Oncology; Tumour biology; Tyrosine kinase

Indexed keywords

FOCAL ADHESION KINASE; LYN PROTEIN-TYROSINE KINASE; PHOSPHOTYROSINE; PROTEIN KINASE FYN; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

ANGIOSARCOMA; ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULAR TUMOR; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOG DISEASES; DOGS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HEMANGIOSARCOMA; MASS SPECTROMETRY; NEOPLASMS, VASCULAR TISSUE; PHOSPHOTYROSINE; PROTEIN-TYROSINE KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-FYN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 84864834814     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2012.00325.x     Document Type: Article

References (31)

1. Vail DM and MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000; 18: 781-792.
2. Koch M, Nielsen GP and Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. Journal of Surgical Oncology 2008; 97: 321-329.
3. Brown NO, Patnaik AK and MacEwen EG. Canine hemangiosarcoma: retrospective analysis of 104 cases. Journal of the American Veterinary Medical Association 1985; 186: 56-58.
4. Hammond TN and Pesillo-Crosby SA. Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005). Journal of the American Veterinary Medical Association 2008; 232: 553-558.
5. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH and Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 2007; 21: 113-120.
6. Cohen LA, Powers B, Amin S and Desai D. Treatment of canine hemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor. Veterinary and Comparative Oncology 2004; 2: 243-248.
7. Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P and Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine 2007; 21: 764-769.
8. Helfand SC. Canine hemangiosarcoma: a tumor of contemporary interest. Cancer Therapy 2008; 6: 457-462. http://cancer-therapy.org/CT/v6/B/HTML/50._Helfand, _457-462.html [accessed 7 March 2012].
9. Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, Wojcieszyn JW, Bellgrau D, Gemmill RM, Hunter LE and Modiano JF. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer 2010; 10: 619-625.
10. Robinson D, He F, Pretlow T and Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proceedings of the National Academy of Sciences 1996; 93: 5958-5962.
11. Kung HJ. Targeting tyrosine kinases and autophagy in prostate cancer. Hormones & Cancer 2011; 2: 38-46.
12. Galliher AJ and Schiemann WP. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Research 2007; 67: 3752-3758.
13. Liang F, Liang J, Wang WQ, Sun JP, Udho E and Zhang ZY. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. The Journal of Biological Chemistry 2007; 282: 5413-5419.
14. Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW and Bruns CJ. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 2007; 10: 167-182.
15. Aleshin A and Finn RS. SRC: a century of science brought to the clinic. Neoplasia 2010; 12: 599-607.
16. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG and Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nature Reviews Cancer 2005; 5: 505-515.
17. Frisch SM, Vuori K, Ruoslahti E and Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. The Journal of Cell Biology 1996; 134: 793-799.
18. Garces CA, Kurenova EV, Golubovskaya VM and Cance WG. Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells. Cancer Research 2006; 66: 1446-1454.
19. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD and Hendrix MJ. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. The American Journal of Pathology 2004; 165: 1087-1095.
20. Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R and Helfand SC. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004; 6: 106-116.
21. Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC and MacEwen EG. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Research in Veterinary Science 2006; 81: 76-86.
22. Brooks PC, Clark RA and Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-571.
23. Keller A, Nesvizhskii AI, Kolker E and Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Analytical Chemistry 2002; 74: 5383-5392.
24. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D and Cance WG. A small molecule inhibitor, 1, 2, 4, 5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. Journal of Medicinal Chemistry 2008; 51: 7405-7416.
25. Calalb MB, Polte TR and Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Molecular and Cellular Biology 1995; 15: 954-963.
26. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA and Doremieux O. PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Research 2003; 31: 334-341.
27. Wang YS, Cao R, Jin H, Huang YP, Zhang XY, Cong Q, He YF and Xu CJ. Altered protein expression in serum from endometrial hyperplasia and carcinoma patients. Journal of Hematology & Oncology 2011; 4: 15.
28. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, Kultz D and Weiss RH. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Molecular Cancer 2006; 5: 64.
29. Panetti TS. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration. Frontiers in Bioscience 2002; 7: d143-d150.
30. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY and Hung MC. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7: 575-589.
31. Kirby GM, Mackay A, Grant A, Woods P, McEwen B, Khanna C, Macri J, Hayes MA and Stalker M. Concentration of lipocalin region of collagen XXVII alpha 1 in the serum of dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 2011; 25: 497-503.